利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

452 条记录 (耗时 0.04 秒)

    IDENTIFICATION OF CRMP4 AS A CONVERGENT REGULATOR OF AXON OUTGROWTH INHIBITION
    32.
    发明公开
    IDENTIFICATION OF CRMP4 AS A CONVERGENT REGULATOR OF AXON OUTGROWTH INHIBITION 审中-公开
    收敛CRMP4作为调节器AXONAUSWUCHSHEMMUNG鉴定

    公开(公告)号：EP2002005A1

    公开(公告)日：2008-12-17

    申请号：EP07710767.0

    申请日：2007-03-19

    申请人： McGill University

    发明人： FOURNIER, Alyson, E. ,  ALABED, Yazan, Z.

    IPC分类号： C12N15/12 ,  A61K38/17 ,  A61P25/28 ,  C07K14/47 ,  G01N33/53

    CPC分类号： C07K14/48 ,  A61K38/00 ,  C07K14/475 ,  G01N33/6896 ,  G01N2500/04

    摘要： The present invention relates to the identification of the cytosolic phosphoprotein CRMP4b as a protein that physically and functionally interacts with RhoA to mediate neurite outgrowth inhibition. siRNA-mediated knockdown of CRMP4 promotes neurite outgrowth on myelin substrates indicating a critical role for CRMP4 in neurite outgrowth inhibition. Disruption of CRMP4b-RhoA binding with a competitive inhibitor attenuates neurite outgrowth inhibition on myelin and aggrecan substrates. Stimulation of neuronal growth cones with Nogo leads to co-localization of CRMP4b and RhoA at discrete regions within the actin-rich central and peripheral domains of the growth cone indicative of a potential function in cytoskeletal rearrangements during neurite outgrowth inhibition. Together these data indicate that a RhoA-CRMP4b complex forms in response to inhibitory challenges in the growth cone environment and regulate cytoskeletal dynamics at distinct sites necessary for axon outgrowth inhibition. Competitive inhibition of CRMP4b-RhoA binding suggests a novel, highly specific therapeutic avenue for promoting regeneration following CNS injury.

    Heteromultimeric ion channel receptor and uses thereof
    37.
    发明公开
    Heteromultimeric ion channel receptor and uses thereof 审中-公开
    异源多聚离子通道受体及其用途

    公开(公告)号：EP1908834A3

    公开(公告)日：2008-04-16

    申请号：EP07018528.5

    申请日：2001-04-20

    申请人： McGill University

    发明人： Seguela, Philippe ,  Babinski, Kazimierz

    IPC分类号： C12N15/12 ,  C07K14/705 ,  C07K16/28 ,  A61K48/00 ,  A61K31/70 ,  C12N15/11 ,  A61K39/395 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/50 ,  G01N33/68

    CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K48/00

    摘要： The present invention describes a heteromultimeric proton-gated ion channel (herein called ASIC-2S.2) with distinctive properties. Compositions and methods are provided for producing and expressing functional ASIC-2S.2 channels, composed of ASIC2A and ASIC3 subunits. The invention also provides genetically engineered expression vectors comprising the nucleic acid sequences encoding both ASIC2A and ASIC3 and host cells coexpressing both ASIC2A and ASIC3 subunits. Also provided herein are genetically engineered nucleic acids encoding chimeric proton-gated ion channels comprised of at least two different subunits, as well as expression vectors and host cells comprising said engineered nucleic acids. The invention also provides for the use of ASIC-2S.2, as well as agonists, antagonists or antibodies specifically binding ASIC-2S.2, in the diagnosis, prevention and treatment of diseases associated with expression of ASIC-2S.2. Also are disclosed methods of influencing electrophysiological, pharmacological and/or functional properties of ASIC-2S.2 as well as methods for screening for substances having ion-channel modulating activity or substances capable of disrupting subunit association or interaction.

    TUBERCULOSIS VACCINE AND METHOD FOR MAKING SAME
    38.
    发明公开
    TUBERCULOSIS VACCINE AND METHOD FOR MAKING SAME 审中-公开
    结核病疫苗和方法及其生产

    公开(公告)号：EP1863914A1

    公开(公告)日：2007-12-12

    申请号：EP06721759.6

    申请日：2006-04-03

    申请人： McGill University

    发明人： BEHR, Marcel ,  MOSTOWY, Serge ,  CHARLET, Danielle ,  ALEXANDER, David

    IPC分类号： C12N15/31 ,  C40B40/06 ,  C12Q1/68 ,  C12P21/02 ,  C12P19/34 ,  C07H21/00 ,  A61K39/04 ,  C12N15/74 ,  C12N1/21 ,  C07K14/35

    CPC分类号： A61K39/04 ,  A61K2039/523 ,  C07K14/35

    摘要： The present invention relates to an improved tuberculosis (TB) vaccine and a method for making this vaccine. The present invention further includes a method for determining the potency of TB strains. Mycobacterium bovis Bacille Calmette-Guerin (BCG) strains are genetically and phenotypically heterogeneous. Expression of the antigenic proteins MPB70 and MPB83 is known to vary considerably across BCG strains; however, the reason for this phenotypic difference has remained unknown. Because the history of BCG strain dissemination has been recorded, it has been possible to precisely determine the chronology of specific genetic changes in BCG strains (Behr and Small, 1999). A number of these mutations affect putative regulatory genes (Behr et al., 1999; Brosch et al ., 2000; Spreadbury et al ., 2005), so it was hypothesized that a mutation in a regulatory gene was likely responsible for the variable production of MPB70 and MPB83. The production of MPB70 and MPB83 across a panel of BCG strains was therefore determined, in order to assign the chronology of this phenotypic change and thereby guide studies towards identifying the responsible mutation. Interestingly, the data implicate a start codon mutation in the M. tuberculosis sigma factor K (RvO445c or sigK) and point to a highly specific link between sigK and expression of MPB70 and MPB83.